We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
PaxVax, Inc. announced today the enrollment of the first patient in its Phase 2b dose-finding trial of the chikungunya virus-like particle vaccine, building upon a Phase 2a study by the National Institutes of Health with 400 subjects